Canntab Therapeutics Limited (CTABF)
| Previous Close | 0.0945 |
| Open | 0.0945 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0945 - 0.0945 |
| 52 Week Range | 0.0945 - 0.6117 |
| Volume | |
| Avg. Volume | 130 |
| Market Cap | 3.872M |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Mar 08, 2016 |
| 1y Target Est | N/A |
- CNW Group
CANNTAB ANNOUNCES ITS ENTRANCE INTO THE NOVA SCOTIA CANNABIS MARKET
Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to provide an update on its recent product delivery of our unique pharmaceutical cannabinoid solutions to the Nova Scotia Liquor Corporation (the "NSLC").
- CNW Group
CANNTAB ANNOUNCES APPOINTMENT OF RICHARD GOLDSTEIN AS INTERIM CEO
Canntab Therapeutics Limited (CSE: PILL.CN)(OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022.
- CNW Group
Canntab Corporate Update
Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing a corporate update to its shareholders and stakeholders. Further to the announcement made by Canntab on April 14, 2022 with respect to our exploration of a variety of alternative business strategies including potential M&A opportunities, as well as identifying and negotiating partnership
